MedTrace Logo

Efficacy and Safety of RC28-E Versus Aflibercept

NCT05727397 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 432

Last updated 2023-08-31

No results posted yet for this study

Summary

This is a randomized, double-masked, multicenter study comparing the the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) versus aflibercept in patients with wet age-related macular degeneration.

Conditions

Interventions

DRUG

RC28-E

Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.

DRUG

Aflibercept

Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.

Sponsors & Collaborators

  • RemeGen Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-14
Primary Completion
2025-11-29
Completion
2025-12-29

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05727397 on ClinicalTrials.gov